InRange publication
InRange diabetes type 1
CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial
Tadej Battelino MD, PhD,Thomas Danne MD,Steve V Edelman MD,Pratik Choudhary MD,Eric Renard MD,Jukka Westerbacka MD, PhD,Bhaswati Mukherjee MD,Valerie Pilorget MD,Mathieu Coudert MSc,Richard M Bergenstal MD
Diabetes Obes Metab. 2022; 1- 11. doi:10.1111/dom.14898
See the result of the InRange study here
Learn more about TiR, the study
design and result of InRange
Relaterade Artiklar